IntroductionLong-acting insulin analogs such as insulin glargine may offer improved glycemic control in patients with type 2 diabetes (T2D) compared to conventional insulin therapies. The objective of this study was to determine whether switching to insulin glargine had beneficial effects on glycemic control, weight gain, and incidence of hypoglycemia in patients with suboptimally managed T2D.MethodsThis prospective observational study was performed on 1041 patients who were suboptimally controlled on pre-mixed insulin therapy and were switched to an insulin glargine regimen. Clinical markers of glycemic control including glycosylated hemoglobin (HbA1c) < 7% (< 53 mmol/mol) and fasting blood glucose (FBG) levels ranging from 3.9 to 7.2 mmol/L were used for the primary outcome measures. Follow-up assessment of primary outcomes, weight gain, incidence of hypoglycemia, and patient satisfaction with the therapy was performed after three and six months of treatment.ResultsTarget therapeutic values of HbA1c were achieved in 9.3% and 30.2% of patients, whereas FBG target values were achieved in 25.9% and 52.3% of patients after the third and sixth month of therapy, respectively. Both the HbA1c and FBG targets were reached in 7% and 25.9% of patients at the third and sixth month of therapy, respectively. Switching to insulin glargine decreased the incidence of hypoglycemia from 49.5% to 5.2% after six months of therapy; this decrease was associated with weight loss and was well perceived by the patients.ConclusionInsulin glargine-based regimens are beneficial and safe therapeutic alternatives for T2D patients inadequately controlled with pre-mixed insulin.FundingSanofi-Aventis Croatia d.o.o., Zagreb, Croatia.Electronic supplementary materialThe online version of this article (10.1007/s13300-018-0467-4) contains supplementary material, which is available to authorized users.
Thyroid cancer remains the most common endocrine malignancy and accounts for almost 1% of human cancer. Early positive diagnosis of thyroid cancer in an apparently benign nodule is sometimes a difficult challenge. Over the past three decades, the incidence of thyroid cancer has increased almost two fold worldwide, without any changes in the mortality rates. The aim of this short communication is to present the actual status of diagnosis and treatment of thyroid cancer in Albania. In our study we have analyzed the preoperative clinical database of 262 patients, divided in 206 females and 56 males, admitted in the Clinic of General Surgery, UHC "Mother Theresa" in Tirana in the timeframe 2004-2011; all with a positive histopathologic diagnosis of thyroid diseases. The histologic types of thyroid cancer cases were: papillary 28 (67%) patients; follicular 10 (24%) patients, medullary 3(7%) and anaplastic 1(2%) patient. Final data obtained from FNAB were: Uncertain-18%; Benign-62%, Suspicious-7% and Malignant -13%. The sensitivity of FNAB was 94%, meanwhile specificity was 96%. The overall incidence of thyroid cancer in albanian population is 0, 6/100 000, being slightly greater in females. Evaluating all thyroid nodules for malignancy is difficult and sometimes unproductive, because thyroid carcinoma is rare. Fine Needle Aspiration Biopsy is the procedure of choice in evaluating suspicious thyroid nodules and was used in all our patients with a sensitivity of 94%. Close collaboration between different specialties is the key to correct preoperative thyroid cancer diagnosis and treatment. FNAB remains the most accurate diagnostic method detecting thyroid cancer. Optimal treatment of thyroid cancer and the associated survival depends mostly in a multidisciplinary treatment approach, focused on surgery. All actual guidelines agree that tot Thyroidectomy and other therapeutic modalities, such as radioiodine treatment or adjuvant radiation are necessary for the maximum survival of these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.